Metropolis Foundation launches 6th edition of MedEngage Scholarship prog

IMT News Desk
IMT News Desk
· 2 min read

MedEngage 2.0 intends to extend scholarships and research grants to 280 medical students

Metropolis Foundation, the Corporate Social Responsibility (CSR) arm of Metropolis Healthcare, has announced the commencement of the 6th edition of the annual ‘MedEngage Scholarship Program 2023-24.’ Applications are now open for scholarships and research grants catering to undergraduate and postgraduate medical students across all years of MBBS education, spanning postgraduate training years of MD / MS / DNB along with the intervening internship year.

As we celebrate a significant five-year milestone coinciding with the establishment of the Metropolis Foundation, in a post-COVID digitised era enriched with advancements like AI and Chat GPT, we acknowledge the compelling need to elevate the MedEngage programme to a more profound and advanced format. This evolution directly responds to the dynamic needs of the current times and the aspirations of our young prodigies.

Dr Duru Shah, Chairperson, Metropolis Foundation, said, “We firmly believe in the pivotal role that education plays in the holistic development of the nation’s youth. We are delighted to support bright young medical students who aspire to make meaningful contributions and require funding for research or thesis endeavours. The MedEngage programme embodies our commitment to enhancing the healthcare research and academic landscape in India. Our goal is to empower and encourage students to actively contribute to the evolving healthcare ecosystem.”

Dr Kirti Chadha, Chief Scientific Officer and Group Head-CSR, Metropolis Healthcare said, “As a socially responsible corporate company and citizens, Metropolis wants to support the young medical talent in the country in multiple ways, by widening the scope of MedEngage programme. We have designed an all-encompassing program that covers academics, research and innovation. Our team of 250+ doctors and 3000+ member scientific team will handhold the students in publishing more research papers and assist them in the pursuit of science, research and innovation.”

Deloitte serves as the process partner for the MedEngage Scholarship Program, with applications evaluated by an eminent panel of jury members from the healthcare fraternity and external bodies. The winners will be announced in February 2024, followed by a felicitation ceremony in March 2024.

 

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk